Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
{{output}}
Background: The FRESCO-2 trial established the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. However, its cost-effectiveness in the US context is not well documented. ... ...
